Improving cellular therapy for primary immune deficiency diseases: Recognition, diagnosis, and management Journal Article
| Authors: | Griffith, L. M.; Cowan, M. J.; Notarangelo, L. D.; Puck, J. M.; Buckley, R. H.; Candotti, F.; Conley, M. E.; Fleisher, T. A.; Gaspar, H. B.; Kohn, D. B.; Ochs, H. D.; O'Reilly, R. J.; Rizzo, J. D.; Roifman, C. M.; Small, T. N.; Shearer, W. T. |
| Article Title: | Improving cellular therapy for primary immune deficiency diseases: Recognition, diagnosis, and management |
| Abstract: | More than 20 North American academic centers account for the majority of hematopoietic stem cell transplantation (HCT) procedures for primary immunodeficiency diseases (PIDs), with smaller numbers performed at additional sites. Given the importance of a timely diagnosis of these rare diseases and the diversity of practice sites, there is a need for guidance as to best practices in management of patients with PIDs before, during, and in follow-up for definitive treatment. In this conference report of immune deficiency experts and HCT physicians who care for patients with PIDs, we present expert guidance for (1) PID diagnoses that are indications for HCT, including severe combined immunodeficiency disease (SCID), combined immunodeficiency disease, and other non-SCID diseases; (2) the critical importance of a high degree of suspicion of the primary care physician and timeliness of diagnosis for PIDs; (3) the need for rapid referral to an immune deficiency expert, center with experience in HCT, or both for patients with PIDs; (4) medical management of a child with suspicion of SCID/combined immunodeficiency disease while confirming the diagnosis, including infectious disease management and workup; (5) the posttransplantation follow-up visit schedule; (6) antimicrobial prophylaxis after transplantation, including gamma globulin administration; and (7) important indications for return to the transplantation center after discharge. Finally, we discuss the role of high-quality databases in treatment of PIDs and HCT as an element of the infrastructure that will be needed for productive multicenter clinical trials in these rare diseases. © 2009 American Academy of Allergy, Asthma & Immunology. |
| Keywords: | child; clinical trial; rituximab; infection; aciclovir; immunoglobulin; pneumocystis pneumonia; hematopoietic stem cell transplantation; practice guidelines as topic; allogeneic hematopoietic stem cell transplantation; cell therapy; cidofovir; virus infection; immune deficiency; cotrimoxazole; bacterial infection; antibiotic prophylaxis; gene therapy; primary immunodeficiency; atovaquone; caspofungin; dapsone; fluconazole; foscarnet; ganciclovir; palivizumab; pentamidine; ribavirin; adenovirus infection; candidiasis; combined immunodeficiency; cytomegalovirus infection; mycosis; newborn screening; severe combined immunodeficiency; immunologic deficiency syndromes |
| Journal Title: | Journal of Allergy and Clinical Immunology |
| Volume: | 124 |
| Issue: | 6 |
| ISSN: | 0091-6749 |
| Publisher: | Mosby Elsevier |
| Date Published: | 2009-12-01 |
| Start Page: | 1152 |
| End Page: | 1160 |
| Language: | English |
| DOI: | 10.1016/j.jaci.2009.10.022 |
| PUBMED: | 20004776 |
| PROVIDER: | scopus |
| PMCID: | PMC2831471 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 5" - "Export Date: 30 November 2010" - "CODEN: JACIB" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work